Antibiotics Market

The Antibiotics Market is valued at USD 54.3 Bn in 2026 and is projected to reach USD 72.4 Bn, growing at a CAGR of 4% by 2033.

Rising Bacterial infections to Influence Demand in Global Antibiotics Market

Growing prevalence of bacterial infections remains instrumental in driving the demand for antibiotics worldwide. Bacterial infections including respiratory infections, urinary tract infections, skin infections, tuberculosis among others have become a global burden. These infections are the primary causes of years of life lost and are a major threat to individuals and economy. Rising occurrences and deaths due to these infections have resulted in the development and use of advanced antibiotics. For instance, according to World Health Organization, approximately 50% of the women population has reported of developing urinary tract infections (UTIs) at some point. Moreover, WHO reveals that around 1.4 million individuals died due to tuberculosis in 2019 and it the infection is among the top 10 causes of mortality worldwide. In addition, growing incidences of respiratory infections is another factor complementing growth of the antibiotics market. As per UNICEF (United Nations International Children’s Emergency Fund), each year, deaths of around 5 million children have been witnessed. Pneumonia is one of the common respiratory infections responsible for about 20% of these mortalities. Such infections have surged the development of new antibacterial drugs, in turn paving potential avenues for the antibiotics market.

AMR to Significantly Impact Antibiotics Market Expansion

Prolonged use of different antimicrobial drugs has resulted in the development of antimicrobial resistance (AMR) in patients. With use of broad spectrum antibiotics, fungi and bacteria have developed the ability to counter antibiotic drugs that were originally designed to nullify them. Resistance to one antibiotic can result in a serious problem and is likely to cause organ failures and prolonged recovery cycles. Misuse of overuse of antimicrobial drugs is the main driver to the development of pathogens that are highly drug resistant.

According to WHO, AMR related economic burden is significant. Along with disability and death, the need for expensive medications, prolonged illness cycle and longer stays in hospitals have financially impacted the economy. In addition, lack of sanitization and clean water facilitates spread of microbes, few of which are likely to be antimicrobial resistant. The cases of AMR have been increasing since past few years and questioning the effectiveness of antibiotics that are devised to treat them. For instance, as per the Centers of Disease Control and Prevention(CDC), over 2.8 million antimicrobial resistance infections are registered in the United States ever year. In addition, antimicrobial resistance has resulted in round 33,000 deaths in the EU. This factor continues to impact the growth of the antibiotics market worldwide.

AMR being a complex situation, it has gained attention of regulatory authorities that are focused on developing a coordinated plan of action to deal with the morbid crisis. World Health Organization has been undertaking a critical review of various fungal infections on the global front. This is in view to develop a potential list of morbid pathogens along with presenting an analysis of the possible antifungal drug development pipeline. The WHO reveals that without new and effective antimicrobials, success of modern medications in treating critical infections would be at high risk. This has further resulted in research for new antifungal drugs or antibiotics that have the ability to lessen the impact of antimicrobial resistant infections. That said, growing awareness apropos to antibiotic resistant infections has pushed biopharmaceutical companies to invest in research and development of advanced and effective combination therapies. For instance, Allecra Therapeutics GmbH, in 2021, invested in the development of enmetazobactam/cefepime as an effort to address resistance issues. The new drug has completed its vital Phase 3 trial in complicated urinary tract infections (cUTIs). Such developments are expected to open vivid opportunities, thus fostering antibiotics market growth.

North America Likely to Slate Dominance in Antibiotics Market

Developed economies in North America are expected to showcase increasing inclination towards use of antibiotics. This is mainly due to increasing prevalence of infectious diseases triggering use of antibiotics that are likely to provide immediate but temporary relief, given the busy schedules of individuals in the region. Furthermore, rising cases of tuberculosis backed by increasing geriatric population are one of the preliminary factors influencing the demand for antibiotics. According to CDC (Centres of Disease Control and Prevention), in 2020 more than 7,000 new tuberculosis cases were registered in United States. Also, according to United Nations, count of individuals aged 65 years and above is projected to increase significantly to touch 84,813,000 in United States by end of 2050. In addition to this, factors such as superior healthcare infrastructure, healthcare spending, stable growth in GDP per capita and rising investments in research and drug development in North America continue to complement growth of the antibiotics market in the region.

Major players in the antibiotics market have been focusing on development of new drugs along with strengthening their position by carrying our collaborations and partnerships. For instance, in 2021, Sandoz acquired the cephalosporin antibiotics business of GSK and now has the rights to Zinnat, Fortum, and Zinacef brands in over 100 markets. This acquisition has strengthened its position as one of the leading antibiotics developing company. Same year, Otsuka Pharmaceuticals Co. Ltd. announced that its German subsidiary Otsuka Novel Products GmbH received regulatory approval from EU commission for Deltyba tablet formulation. This Deltyba formulation will contribute in treating Multidrug-Resistant Tuberculosis (MDR-TB) among children. This move was an effort towards pursuing SDG (Sustainable Development Goals) in fighting AMR worldwide.

A few of the major players in global antibiotics market include:

• Pfizer Inc.
• GlaxoSmithKline plc
• Merck & Co., Inc.
• Johnson & Johnson
• Novartis AG
• Sanofi
• Abbott Laboratories
• Bayer AG
• Eli Lilly and Company
• AstraZeneca plc
• Cipla Ltd.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Aurobindo Pharma Ltd.
• Dr. Reddy's Laboratories Ltd.

The Global Antibiotics Market Is Segmented As Below:

By Drug Class

• Penicillin
• Cephalosporin
• Aminoglycosides
• Tetracycline
• Macrolides
• Fluoroquinolones
• Sulfonamides
• Others

By Application

• Skin Infections
• Respiratory Infections
• Urinary Tract Infections
• Septicemia
• Ear Infection
• Gastrointestinal Infections
• Others

By Route of Administration

• Oral
• Parenteral
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa